Protagonist Therapeutics' stock plunges after colitis treatment trial deemed 'futile' [MarketWatch]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: MarketWatch
Protagonist Therapeutics' stock plunges after colitis treatment trial deemed 'futile' Protagonist Therapeutics Inc.'s stock PTGX, -58.11% plunged 56% toward a 10-month low in morning trade Monday, after biopharmaceutical company said it was discontinuing its phase 2 trial of its ulcerative colitis treatment after an independent data monitoring committee (DMC) deemed the trial "futile." The DMC said its recommendation was based on analysis of the primary endpoint of clinical resubmission. The company said based on the DMC's recommendation, further treatment of patients currently in the study will be discontinued, and it will postpone its decision regarding the initiation of a phase 2/3 trial. "We are very disappointed with this futility-based outcome which was also accompanied by an unexpectedly high placebo rate," said Chief Executive Dinesh Patel. "We will conduct an extensive review of the complete dataset on the totality of patients enrolled in the trial before making any furthe
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Turnstone Biologics Appoints William Waddill to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Hemochromatosis Pipeline Insight Report 2024, Featuring Protagonist Therapeutics, Sirnaomics and Bond Biosciences [Yahoo! Finance]Yahoo! Finance
- Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135% [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataAccesswire
PTGX
Earnings
- 8/3/23 - Miss
PTGX
Sec Filings
- 4/19/24 - Form 4
- 4/12/24 - Form PRE
- 4/2/24 - Form 4
- PTGX's page on the SEC website